Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients

Respiratory Medicine

Volumn 107, Issue 1, 2013, Pages 75-83

  Vogelmeier, Claus ^a   Fabbri, Leonardo M ^b   Rabe, Klaus F ^c   Beeh, Kai Michael ^d   Schmidt, Hendrik ^e   Metzdorf, Norbert ^e   Glaab, Thomas ^e  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF KIEL   (Germany)

^d Institut fur Atemwegsforschung INSAF   (Germany)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

COPD; Exacerbations; GOLD stage II; Maintenance therapy; Salmeterol; Tiotropium

Indexed keywords

CORTICOSTEROID; SALMETEROL; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HAZARD RATIO; HEART DISEASE; HOSPITALIZATION; HUMAN; INFECTION; INFESTATION; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METERED DOSE INHALER; NEOPLASM; NEUROLOGIC DISEASE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SMOKING; THORAX DISEASE; TREATMENT OUTCOME; VASCULAR DISEASE;

ADULT; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871373004     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2012.09.015     Document Type: Article

References (16)

1. G.C. Donaldson, T.A. Seemungal, A. Bhowmik, and J.A. Wedzicha Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease Thorax 57 2002 847 852
2. T.A. Seemungal, G.C. Donaldson, A. Bhowmik, D.J. Jeffries, and J.A. Wedzicha Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 161 2000 1608 1613
3. J.J. Soler-Cataluna, M.A. Martinez-Garcia, and S.P. Roman Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease Thorax 60 2005 925 931
4. S. Spencer, and P.W. Jones Time course of recovery of health status following an infective exacerbation of chronic bronchitis Thorax 58 2003 589 593
5. J.A. Wedzicha, and T.A. Seemungal COPD exacerbations: defining their cause and prevention Lancet 370 2007 786 796
6. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Global Initiat Chronic Obstruct Lung Dis Website 2011 [serial online] [accessed 28.02.12]
7. M. Decramer, and C.B. Cooper Treatment of COPD: the sooner the better? Thorax 65 2010 837 841
8. T. Troosters, B. Celli, and T. Lystig Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial Eur Respir J 36 2010 65 73
9. C. Vogelmeier, B. Hederer, and T. Glaab Tiotropium versus salmeterol for the prevention of exacerbations of COPD N Engl J Med 364 2011 1093 1103
10. K.M. Beeh, B. Hederer, and T. Glaab Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations Int J Chron Obstruct Pulmon Dis 4 2009 119 125
11. M. Decramer, B. Celli, and S. Kesten Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial Lancet 374 2009 1171 1178
12. C.R. Jenkins, P.W. Jones, and P.M. Calverley Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study Respir Res 10 2009 59
13. P.M.A. Calverley, J.A. Anderson, and B. Celli Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease N Engl J Med 356 2007 775 789
14. J.A. Wedzicha Choice of bronchodilator therapy for patients with COPD N Engl J Med 364 2011 1167 1168
15. R. Dahl, K.F. Chung, and R. Buhl Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
16. J. Wang, B. Nie, W. Xiong, and Y. Xu Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a metaanalysis J Clin Pharm Ther 37 2012 204 211